Sangamo Selects PTC and Lilly as Winning Bidders in $163.55M Asset Auction
SGMOQ has more than doubled off its 52-week low of $0.03.
Summary
Sangamo Therapeutics announced winning bidders in its bankruptcy asset auction: PTC Therapeutics for the Fabry disease program ($111M cash + up to $100M milestones) and Eli Lilly for platform technologies and prion disease program ($50M cash), totaling approximately $163.55 million in cash consideration at closing.
Key Events · M&A and Partnerships · SGMOQ
-
Winning Bidders Selected
PTC Therapeutics selected for Fabry disease program (ST-920) at $111M cash plus up to $100M in milestones; Eli Lilly selected for capsid delivery, zinc finger, MINT platforms, and prion disease program (ST-506) at $50M cash.
-
Total Cash Consideration
Approximately $163.55 million in cash at closing, including $2.55 million from tools and equipment sales to various bidders.
-
Milestone Structure
PTC deal includes up to $100 million in future milestones: $80 million upon FDA accelerated approval and $20 million upon traditional or full approval.
-
Closing Timeline
Lilly transaction expected to close on or about September 4, 2026; PTC transaction expected to close following HSR antitrust review. Sale hearings expected in Q3 2026.
Analysis · SGMOQ · Life Sciences
Sangamo Therapeutics, operating under Chapter 11 bankruptcy protection, has selected winning bidders for its key assets following a court-supervised auction. PTC Therapeutics will acquire the Fabry disease program for $111 million in cash plus up to $100 million in milestone payments, while Eli Lilly will acquire the capsid delivery, zinc finger, and MINT platforms along with the prion disease program for $50 million. Additional tools and equipment sales bring total cash consideration at closing to approximately $163.55 million. The transactions remain subject to bankruptcy court approval and regulatory clearances, with the Lilly deal expected to close around September 4, 2026, and the PTC deal following HSR review. For a company with a market cap of only $63.6 million, this asset sale represents a transformative liquidity event that will determine the ultimate recovery for stakeholders in the Chapter 11 case.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 42.1% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGMOQ was trading at $0.16 on OTC in the Life Sciences sector, with a market capitalization of approximately $63.6M. The 52-week trading range was $0.03 to $0.77. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.